Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGT103-T in HIV
NCT04561258Phase 1Completed
- Sponsor
- American Gene Technologies
- Start
- Oct 2020
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Adoptive Cell Transfer, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of AGT103-T in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by American Gene Technologies. Primary endpoint: Adverse Events. Started Oct 2020; status: completed.
02
Drugs
AGT103-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04561258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561258.